Apr. 2005
history_yamanouchi_fujisawa

Astellas Pharma Inc. (Astellas) was established by merging the former Yamanouchi Pharmaceutical Co., Ltd. and the former Fujisawa Pharmaceutical Co., Ltd.

Apr. 2006
optimization_of_resource_allocation

Astellas sold Zephama, operating in the over-the-counter drug business, to Daiichi Sankyo Co., Ltd. in Japan to concentrate Astellas' managerial resources on its ethical drug business.

Oct. 2007
geninax
launch_of_new_products

Astellas launched Geninax®, an oral new-type quinololone antibacterial agent, in Japan.

Dec. 2007
building_a_platform_to_support_growth

Astellas acquired Agensys, Inc., a biotechnology company specialized in therapeutic antibody research and development in cancer in the U.S.

June 2010
building_a_platform_to_support_growth
Astellas acquired OSI Pharmaceuticals, Inc., a biotechnology company in the U.S. to create an oncology platform.
July 2011
launch_of_new_products

Astellas launched Betanis® in Japan for the treatment of overactive bladder (OAB).

Nov. 2011
initiatives_to_support

Astellas signed United Nations Global Compact.

Mar. 2012
ireland_plants
initiatives_to_support

Astellas launched a wind turbine power generation station and a woodchip biomass boiler in the Kerry Plant in Ireland.

July 2012
initiatives_to_support

Astellas participated in the new public-private partnership to develop a treatment for schistosomiasis-infected preschool children.

Sept. 2012
launch_of_new_products

Astellas launched XTANDI® in the U.S. for the treatment of metastatic castration-resistant prostate cancer.

Oct. 2012
launch_of_new_products

Astellas launched Gonax® in Japan for the treatment of prostate cancer.

Oct. 2012
initiatives_to_support

Astellas entered collaborative new drug discovery research with the National Institute of Advanced Industrial Science and Technology (AIST) for neglected tropical diseases caused by protozoan parasites.

Oct. 2012
launch_of_new_products

Astellas launched MYRBETRIQ® in the U.S. for the treatment of OAB.

Mar. 2013
cimzia
launch_of_new_products

Astellas and UCB Japan launched Cimzia® in Japan for the treatment of adult patients with rheumatoid arthritis.

Apr. 2013
initiatives_to_support

Astellas announced participation in Global Health Innovative Technology Fund (GHIT Fund).

May 2013
astellas_and_amgen
building_a_platform_to_support_growth

Astellas and Amgen concluded an agreement for established alliance innovative joint venture, Astellas Amgen Biopharma in Japan.

Apr. 2014
suglat
launch_of_new_products

Astellas launched Suglat® in Japan for the treatment of type 2 diabetes.

May 2014
initiatives_to_support

Astellas funded a €1.5 million groundbreaking programme to tackle obstetric fistula in Kenya.

May 2014
xtandi
launch_of_new_products

Astellas launched XTANDI® in Japan for the treatment of prostate cancer.

Feb. 2016
ocata
building_a_platform_to_support_growth

Astellas acquired Ocata Therapeutics, Inc., a biotechnology company in the U.S. to enable Astellas to establish a presence in ophthalmology and a leading position in cell theapy.

Apr. 2016
repatha
launch_of_new_products

Astellas launched Repatha® in Japan for the treatment of high cholesterol.

Oct. 2016
initiatives_to_support
Astellas and World Anti-Doping Agency announced global initiative to prevent misuse and abuse of medicines for doping in sports.
Dec. 2016
ganymed
building_a_platform_to_support_growth

Astellas acquired Ganymed Pharmaceticals AG, a biopharmaceutical company, in Germany to further expand Astellas' oncology presence by adding anti-body program, zolbetuximab.

Jan. 2017
initiatives_to_support

Astellas participated in Access Accelerated, a global initiative aimed at improving access to non-communicable diseases prevention, diagonosis and treatment.

Mar. 2017
linzess
launch_of_new_products

Astellas launched LINZESS® in Japan for the treatment of irritable bowel syndrome with conspitation.

May 2017
ogeda
building_a_platform_to_support_growth

Astellas acquired Ogeda SA, a drug discovery company, in Belgium to expand Astellas' pipeline by adding a selective NK3 receptor atagonist, fezolinetant.

Oct. 2017
initiatives_to_support
Astellas entered into a new collaborative research agreement with TB Alliance to discover anti-tuberculosis drugs.
Oct. 2017
initiatives_to_support

Astellas entered into a screening collaboration agreement with Medicines for Malaria Venbure to discover antimalarial drugs.

Jan. 2018
mitobridge
building_a_platform_to_support_growth

Astellas acquired Mitobridge, Inc., a bio-venture company in the U.S. to accelerate Astellas' research and development in diseases associated with mitochondrial dysfunctions.

Feb. 2018
universalcells
building_a_platform_to_support_growth

Astellas acquired Universal Cells, Inc., a bio-venture company which has ability to produce pluripotent stem cells that have lower immunological rejections.

Mar. 2018
initiatives_to_support

Astellas participated in Neglected Tropical Diseases Drug Discovery Booster Consortium with DNDi and Seven Other Pharmaceutical Companies.

Aug. 2018
quethera
building_a_platform_to_support_growth

Astellas acquired Quethera, a gene theraphy company in the U.K. to further Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma.

Sept. 2018
Dafclir
launch_of_new_products

Astellas launched Dafclir® in Japan for the treatment of infectious enteritis caused by Clostridium difficile.

Oct. 2018
rx_business

Astellas and BANDAI NAMCO Entertainment Inc. concluded an agreement for joint development of application for smartphone exercise support application.

Nov. 2018
initiatives_to_support

Science Based Targets Initiative approved Astellas’ greenhouse gas reduction plan.

Nov. 2018
blincyto
launch_of_new_products

Astellas launched BLINCYTO® in Japan for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.

Nov. 2018
initiatives_to_support

Astellas launched the Astellas Global Health Foundation to support improving access to health for underserved populations.

Dec. 2018
xospata
launch_of_new_products

Astellas launched XOSPATA® in Japan to provide a therapeutic option for the treatment of Acute Myeloid Leukemia.

Dec. 2018
potenza
building_a_platform_to_support_growth

Astellas acquired Potenza Therapeutics Inc. in the U.S. to add clinical stage novel immuno-oncology programs to Astellas' oncology pipeline.

Mar. 2019
evenity
launch_of_new_products

Astellas launched EVENITY® in Japan for the treatment of osteoporosis.

July 2019
smyraf
launch_of_new_products
Astellas launched Smyraf® in Japan for the treatment of rheumatoid arthritis in patients.
Nov. 2019
evrenzo
launch_of_new_products

Astellas launched Evrenzo® in Japan for the treatment of renal anemia in patients on dialysis.

Nov. 2019
rx_business
Astellas entered into strategic alliance for digital therapeutics with Welldoc, Inc., a digital health company.
Dec. 2019
xyphos
building_a_platform_to_support_growth

Astellas acquired Xyphos Biosciences, Inc., a biotechnology company in the U.S. to accelerate next-generation cancer immunotherapy.

Dec. 2019
launch_of_new_products

Astellas lauched PADCEV® in the U.S. for the treatment of urothelial cancer.

Jan. 2020
audentes
building_a_platform_to_support_growth

Astellas acquired Audentes Therapeutics, Inc., a biotechnology company in the U.S. to complement capabilities and resources of Astellas for creating an industry-leading gene therapy company.

Apr. 2020
nanna
building_a_platform_to_support_growth

Astellas acquired Nanna Therapeutics Limited, in the U.K. to accelerate Astellas' research in diseases associated with mitochondrial dysfunctions.

June 2020
rx_business

Astellas, City of Yokohama, and Yokohama City University developed science-based exercise programs through industry-government-academia collaboration.

Sept. 2020
rx_business

Astellas launched science-based fitness service, Fit-eNce®.

Oct. 2020
rx_business

Astellas acquired iota Biosciences, Inc. in the U.S. to explore new biosensing and treatment measures using ultra-small implantable medical devices.

Dec. 2020
initiatives_to_support

Astellas supported recommendations of Task Force on Climate-related Financial Disclosures (TCFD).

 

Icon Description:

launch_of_new_products

​Launch of New Products

building_a_platform

Building a Platform to Support Growth

optimization_of_resourc

Optimization of Resource Allocation

initiatives_to_support_society_and_companys_sustainable_growth

Initiatives to Support Society and Company's Sustainable Growth

rx_business

Rx+® Business​